top of page
Executive Spotlights

Voyager Therapeutics Stock Inks a $1.2B Agreement with Novartis

Cambridge, MA¸ January 02, 2024 (Reuters) -- Voyager Therapeutics (VYGR.O) announced a strategic collaboration with the Swiss-based pharmaceutical company Novartis (NOVN.S). Under this licensing agreement, Novartis will make an upfront payment of $100 million to Voyager. Additionally, Voyager stands to receive up to $1.2 billion upon reaching specific milestones.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page